Faculty and Staff Detail
|
Susan Fagan, Pharm.D., BCPS, FCCP Albert W. Jowdy Professor Associate Department Head Assistant Dean--MCG Program CET |
| Contact Information | |
|---|---|
| Phone: | (706)721-0130 |
| Email: | sfagan@mail.mcg.edu |
| Fax: | (706)721-3994 |
| Office: | HM-1220 |
| Address: |
Medical College of Georgia UGA Clinical Pharmacy Program HM-1200 Augusta, GA 30912 |
| Biosketch | |||
|---|---|---|---|
| Research Pharmacist | Augusta VA Medical Center | Augusta, GA | 01/2000-Present |
| Adjunct Professor of Neurology | Medical College of Georgia | Augusta, GA | 11/1999-Present |
| Professor | University of Georgia | Augusta, GA | 10/1999-Present |
| Professor | Wayne State University | Detroit, MI | 09/1999-10/1999 |
| Associate Professor | Wayne State University | Detroit, MI | 08/1992-08/1999 |
| Assistant Professor | Wayne State University | Detroit, MI | 07/1986-08/1992 |
| Sabbatical - Stroke Research | UCSD Neuroscience | LaJolla, CA | 1994 |
| Fellowship - Neuropharmacology | Dent Neurologic Institute | Buffalo, NY | 1986 |
| PharmD | State University of New York at Buffalo | Buffalo, NY | 1984 |
| BSC - Pharmacy | Dalhousie University | Halifax, NS, Canada | 1980 |
- Honors and Awards
- Awards/Honors: Board Certification – Pharmacotherapy, Board of Pharmaceutical Specialities; Gustavus Pfeiffer Faculty Fellowship Award, AFPE, 1993; Fellowships: ACCP (1995), AHA Stroke Council (1994), Member; Prevention Advisory Board, National Stroke Association (2003); Member-at-Large, Leadership
Committee of AHA Stroke Council (2005); Study Sections: AHA Brain 1 (2003 -2007); BDCN-L (90)S (2004-2006); NSD K (2005-2007); Co-Director, Program in Clinical and Experimental Therapeutics, UGA (2007-);Chair, Research Institute Board of Trustees, ACCP (2008- ); Program Committee, NINDS Clinical Trial Methods Course (2008).
- Area of Expertise
- • Stroke Pharmacotherapy
• Neurovascular injury after ischemia
- Representative Publications
- Relevant Publications (28 out of 113 peer-reviewed publications):
1.Bowes MP, Rothlein R, Fagan SC, Zivin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance the efficacy of thrombolytic therapy. Neurology 1995;45:815-819
2. The National Institute of Neurological Disorders and Stroke rt-TPA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
3. Bowes MP, Thomas GR, Thibodeaux H, Fagan SC, Zivin JA: Acute hypertension, but not thrombolysis, increases the incidence and severity of cerebral hemorrhage in rabbits. Exp Neurol, 1996; 141(1):40-46
4. Knight RA, Barker PB, Fagan SC, Li Y, Jacobs MA, Welch KMA: Prediction of impending hemorrhagic transformation in ischemic stroke using Magnetic Resonance Imaging. Stroke 1998;29:144-151
5. Fagan SC, Bowes MP, Lyden PD, Zivin JA: Acute hypertension promotes hemorrhagic infarction in a rabbit embolic stroke model. Effect of labetalol. Exp Neurol 1998;150:153-158
6. Brott TG, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC: Hypertension and its treatment in the NINDS t-PA Stroke Study. Stroke 1998;29:1504-1509
7. Fagan SC, Garcia JH: Hemorrhagic transformation in focal cerebral ischemia: Effect of time to artery reopening and tissue plasminogen activator. Pharmacotherapy 1999;19:139-142
8. Brott TG, Grotta JC, Latchaw RE, Starkman S, Jauch E, Clark WM, Fagan SC, Hopkins LN: Stroke The First Hours. Consensus Statement. October, 2000; National Stroke Association
9. Hess DC, Fagan SC: Pharmacology and clinical experience with simvastatin. Exp Opinion in Pharmacother 2001;2(1):153-163
10. Fagan SC: Hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. J Inform Pharmacother (online) 2001;4:300-305
11. Grotta JC, Welch KMA, Fagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD and the NINDS rt-PA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke
2001;32:661-668
12. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC, Brott TG, Grotta J and the NINDS rt-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001; 49:736-744
13. Lyden P, Lu M, Kwiatkowski T, Frankel M, Levine S, Broderick J, Brott T and the NINDS rt-PA Stroke Study Group: Thrombolysis in patients with transient neurologic deficits. Neurology 2001;57:2125-2128
14. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR: Neuroprotective agents for clinical trials in Parkinson’s Disease: A systematic assessment. Neurology 2003; 60: 1234
15. Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA: Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a non-embolic stroke model. Neurol Res 2003; 25: 377-382
16. Hilali HM, Simpkins AN, Hill WD, Waller JL, Knight RA, Fagan SC: Single slice method for quantification of hemorrhagic transformation using Direct ELISA. Neurol Res 2004; 26:93-98
17. Fagan SC, Edwards DJ, Borlongan C, Xu L, Arora A, Feuerstein G, Hess DC. Optimal delivery of minocycline to the brain. Implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-251
18. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Lowdose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurology 2004; 4:7
19. Fagan SC, Hess DC, Pollock DM, Hohnadel EJ, Ergul A. Targets for vascular protection after ischemic stroke. Stroke 2004; 35:35:2220-2225
20. Fagan SC, Hess DC, Machado LS, Hohnadel EJ, Pollock DM, Ergul A. Tactics for vascular protection after acute ischemic stroke. Pharmacotherapy 2005;25(3): 387-395
21. Knight RA, Nagesh V, Nagaraja TN, Ewing JR, Nagesh V, Whitton PA, Bershad E, Fagan SC, Fenstermacher JD. Acute blood-brain barrier opening in experimentally induced focal cerebral ischemia is preferentially identified by quantitative magnetization transfer imaging. Magn Reson Med 2005;54(4):822-832
22. Harris AK, Ergul A, Kozak A, Machado LS, Johnson MH, Fagan SC: Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neuroscience, 2005; 6:49
23. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC: Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006;24:535-539
24. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC: Minocycline for short-term neuroprotection. Pharmacotherapy 2006; 26(4):515-521
25. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated MMP 2 and 9 after experimental stroke. BMC Neuroscience 2006;7:56
26. Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC: Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens 2007; 25: 855-859
27. Ergul A, Elgebaly MM, Middlemore ML, Li W, Switzer JA, Hall C, Kozak A, Fagan SC. Increased Hemorrhagic Transformation And Altered Infarct Size And Localization After Experimental Stroke In A Rat Model of Type 2 Diabetes. BMC Neurology 2007: 7:33
28. Fagan SC, Elewa HF, Rychly DJ. Secondary Stroke Prevention with Statin Therapy. Evidence Catches up to Practice. J Pharmacy Practice 2007; 20:2:117-122
- Other
- My entire research program revolves around the importance of vascular protection in the acute stroke period to improve outcome of ischemic stroke. I perform both late preclinical and clinical investigations on interventions that are vascular protective.
My Stroke Laboratory has focused on identifying the mediators and protectors of the vasculature after focal cerebral ischemia and reperfusion (see Figure above from Fagan, Stroke, 2004). Also, we have tried to identify tactics for decreasing vascular damage after ischemic stroke in an attempt to develop new therapies for stroke patients. Using animal models of temporary cerebral ischemia, we have performed studies that test translatable treatments that may be brought to humans. Research in the laboratory has been funded by grants from NIH-NINDS, AHA, VA Merit Review and pharmaceutical industry.
We are interested in identifying new targets and the modulating influence of preexisting disease on neurovascular outcome after ischemic stroke. We are particularly interested in the following:
- The role of the neutrophil in the initiation of early vascular damage after reperfusion.
- The effect of MMP inhibition on hemorrhagic transformation after ischemic stroke.
- The effect of hypertension on neurovascular outcome after ischemic stroke.
- The importance of vascular protection after reperfusion therapy with tPA.
- The use of biomarkers in the acute stroke period in humans and animal models to predict neurovascular outcome.